Keyphrases
Retrospective Comparison
100%
Ovarian Cancer
100%
Paclitaxel
100%
Carboplatin
100%
Weekly Schedule
100%
Elderly Patients
40%
Older Patients
40%
Low Incidence
20%
Comorbidity
20%
Medical Records
20%
Adverse Effects
20%
Consecutive Patients
20%
Demographic Characteristics
20%
Clinical Characteristics
20%
Treatment Options
20%
Implications for Practice
20%
Retrospective Analysis
20%
Neutropenia
20%
Hazard Ratio
20%
Cox Proportional Hazards Model
20%
Combination Therapy
20%
First-line Therapy
20%
Improved Survival
20%
Safety Profile
20%
Antiangiogenic Activity
20%
Residual Disease
20%
Clinical Efficacy
20%
Neoadjuvant
20%
Frail Elderly
20%
Holidays
20%
Neuropathy
20%
Modified Protocol
20%
Treatment Delay
20%
Completion Rate
20%
Alopecia
20%
Clinical Toxicity
20%
Off-treatment
20%
Median Overall Survival
20%
Advanced Ovarian Cancer
20%
Median Progression-free Survival
20%
6-cycles
20%
Weekly Paclitaxel
20%
Weekly Regimen
20%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Paclitaxel
100%
Carboplatin
100%
Comorbidity
16%
Adverse Event
16%
Combination Therapy
16%
Minimal Residual Disease
16%
Progression Free Survival
16%
Overall Survival
16%
Neuropathy
16%
Antiangiogenic
16%
Neutropenia
16%
Alopecia
16%